These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 32259643)

  • 1. Nanoparticle mediated cancer immunotherapy.
    Gupta J; Safdari HA; Hoque M
    Semin Cancer Biol; 2021 Feb; 69():307-324. PubMed ID: 32259643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Delivery for Cancer Immunotherapy and Vaccines.
    Batty CJ; Tiet P; Bachelder EM; Ainslie KM
    Pharm Nanotechnol; 2018; 6(4):232-244. PubMed ID: 30227827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
    Aikins ME; Xu C; Moon JJ
    Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy.
    Huang P; Wang X; Liang X; Yang J; Zhang C; Kong D; Wang W
    Acta Biomater; 2019 Feb; 85():1-26. PubMed ID: 30579043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nano-immunotherapy: Overcoming tumour immune evasion.
    Guevara ML; Persano F; Persano S
    Semin Cancer Biol; 2021 Feb; 69():238-248. PubMed ID: 31883449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy.
    Bai Y; Wang Y; Zhang X; Fu J; Xing X; Wang C; Gao L; Liu Y; Shi L
    Int J Pharm; 2019 Oct; 570():118636. PubMed ID: 31446027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
    Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
    J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy.
    Lim S; Park J; Shim MK; Um W; Yoon HY; Ryu JH; Lim DK; Kim K
    Theranostics; 2019; 9(25):7906-7923. PubMed ID: 31695807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy.
    Wells K; Liu T; Zhu L; Yang L
    Nanoscale; 2024 Oct; 16(38):17699-17722. PubMed ID: 39257225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
    Phuengkham H; Ren L; Shin IW; Lim YT
    Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanovaccines: Immunogenic tumor antigens, targeted delivery, and combination therapy to enhance cancer immunotherapy.
    Jahanafrooz Z; Oroojalian F; Mokhtarzadeh A; Rahdar A; Díez-Pascual AM
    Drug Dev Res; 2024 Aug; 85(5):e22244. PubMed ID: 39138855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
    Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
    J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-based nanosystems: the next generation of cancer immune therapy.
    Cheng Z; Fobian SF; Gurrieri E; Amin M; D'Agostino VG; Falahati M; Zalba S; Debets R; Garrido MJ; Saeed M; Seynhaeve ALB; Balcioglu HE; Ten Hagen TLM
    J Hematol Oncol; 2024 Jul; 17(1):53. PubMed ID: 39030582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting myeloid cells using nanoparticles to improve cancer immunotherapy.
    Amoozgar Z; Goldberg MS
    Adv Drug Deliv Rev; 2015 Aug; 91():38-51. PubMed ID: 25280471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smart Nanoparticle-Based Platforms for Regulating Tumor Microenvironment and Cancer Immunotherapy.
    Cheng R; Santos HA
    Adv Healthc Mater; 2023 Mar; 12(8):e2202063. PubMed ID: 36479842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Nanoparticle-Based Targeted Drug-Delivery Systems Against Cancer and Role of Tumor Microenvironment.
    Ashfaq UA; Riaz M; Yasmeen E; Yousaf MZ
    Crit Rev Ther Drug Carrier Syst; 2017; 34(4):317-353. PubMed ID: 29199588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologically based strategies for overcoming in vivo barriers with functional nano-delivery systems.
    Ahmadzadeh R; Taheri SA; Mohammadi N; Hjazi A; Menon SV; Kadhum WR; Kumar A; Shakir MN; Shayan FK; Shirinkami N
    J Biochem Mol Toxicol; 2024 Aug; 38(8):e23782. PubMed ID: 39115384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.